STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Adage, Atchinson, Gross report zero INZY ownership in 13G/A

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Adage Capital Management, L.P., together with principals Robert Atchinson and Phillip Gross, filed an Amendment to Schedule 13G for Inozyme Pharma, Inc. (INZY). The filing reports 0.00 shares beneficially owned and 0% of the class, with sole and shared voting and dispositive power all shown as 0. The issuer's principal executive office is listed at 321 Summer Street, Suite 400, Boston, MA, and the reporting persons' business address is 200 Clarendon Street, 52nd Floor, Boston, MA. Signatures dated 08/12/2025 certify the information and state the securities were not acquired to influence control.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Adage's 13G/A shows no ownership of INZY, so there is no material ownership stake or voting influence reported.

The filing explicitly reports 0.00 shares and 0% beneficial ownership for Adage Capital Management, L.P., and the named individuals. That means the reporting persons do not hold a reported economic or voting position in Inozyme Pharma under this filing. For investors, this disclosure is informational and does not reflect an active stake or change in ownership that would affect company control or capital structure.

TL;DR: Formal Schedule 13G/A filing with certifications; no indication of control intent or group ownership.

The statement includes the standard certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control. Item responses show ownership of 5 percent or less and Items 6–9 are marked Not Applicable. Signatures from Adage and the two individuals dated 08/12/2025 complete the filing. Procedurally sound but not material to governance given the reported 0% ownership.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:08/12/2025
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:08/12/2025
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:08/12/2025

FAQ

What does the Schedule 13G/A filed for INZY state about ownership?

The filing reports 0.00 shares beneficially owned and 0% of the class by Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross.

Who filed the Schedule 13G/A for Inozyme Pharma (INZY)?

The statement was filed by Adage Capital Management, L.P. and principals Robert Atchinson and Phillip Gross.

What are the relevant dates in the INZY 13G/A filing?

The Date of Event requiring the filing is listed as 06/30/2025 and the signatures on the amendment are dated 08/12/2025.

What addresses are listed in the INZY Schedule 13G/A?

Issuer principal executive offices: 321 Summer Street, Suite 400, Boston, MA 02210. Reporting persons' business address: 200 Clarendon Street, 52nd Floor, Boston, MA 02116.

Does the filing indicate any intent to influence control of Inozyme (INZY)?

The certification in the filing states the securities were not acquired and are not held for the purpose of changing or influencing control.
Inozyme Pharma, Inc.

NASDAQ:INZY

INZY Rankings

INZY Latest News

INZY Latest SEC Filings

INZY Stock Data

257.60M
63.15M
Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparations
Link
US
BOSTON